Hematology · Acute Myeloid LeukemiaTrial Updateclinicalmid-term

Phase 1 Study of Tomivosertib in Relapsed/Refractory AML Initiates Dose Finding

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/2/2026, 6:31:39 PM

Assessment confidence: 61% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of the Phase 1 trial for tomivosertib in relapsed or refractory AML is significant as it may introduce a new competitive treatment option in a challenging therapeutic area. Monitoring the trial's progress is essential for understanding its potential impact on market dynamics and positioning against existing therapies. Regulatory context from MHRA (Research: National Commission into the Regulation of AI in Healthcare: research, engagement and call for evidence findings) supports the near-term read. Assessment grounded in 17 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should monitor the trial's progress closely, as successful dosing could enhance tomivosertib's market positioning against existing therapies. The strongest clinical anchor is Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (ClinicalTrials.gov), sponsor/company relevance (merck); patient population match (refractory). In Hematology · Acute Myeloid Leukemia, 3 regulatory and 3 competitive items passed relevance filtering for Tomivosertib.

Competitive Pressure

Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study.

Regulatory Outlook

Regulatory risk is concentrated around Research: National Commission into the Regulation of AI in Healthcare: research, engagement and call for evidence findings (MHRA). Moderate corpus alignment. Relevant agencies in corpus: MHRA, FDA. The trial's design and outcomes will influence future regulatory submissions and labeling, especially if the dosing strategy proves effective in combination therapies.

Key Risks

Elevated medium regulatory exposure for Tomivosertib could delay market entry or constrain labeling if agency review intensifies.
Competitive risk from Humanexa Signals (Study on Multivirus CTL for Viral Infections Post Allogeneic SCT Shows Promise) could weigh on Tomivosertib through competitive crowding and share erosion if follow-through weakens.

Key Opportunities

Successful dosing outcomes could enhance tomivosertib's market share and revenue potential, particularly if it demonstrates superior efficacy or safety compared to current AML treatments.
Bristol Myers Squibb document relevant to the signal.
Upside for Tomivosertib may improve if Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas (ClinicalTrials.gov) delivers favorable follow-through.
Lead sponsor: Bausch & Lomb Incorporated.
Upside for Tomivosertib may improve if An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Key milestones include the completion of the dose finding phase and the determination of the recommended starting dose for combination therapies.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Research: National Commission into the Regulation of AI in Healthcare: research, engagement and call for evidence findings
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Frutas Hortalizas del Sur S.A. Initiates Recall of Frozen GreenWise Organic IQF Blueberries Due to Potential E.
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves First Single-Dose Generic Treatment for Influenza
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck); Patient population match (refractory)
FDA document
View source
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View source
A Phase 1 Clinical Study in Healthy Participants
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study Evaluating the Safety and Efficacy of Fixed-Dose Combination for Dry Eye Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Patient population match (refractory)
FDA document
View source
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Study on Multivirus CTL for Viral Infections Post Allogeneic SCT Shows Promise
Humanexa Signalsmedium relevance
Moderate corpus alignment

Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedhigh relevance
Patient population match (refractory)
FDA document
View source
Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.
PubMedhigh relevance
Patient population match (refractory)
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Raloxifene inhibits the proliferation of pediatric acute myeloid leukemia by targeting the ANP32B gene and regulating C-MYC expression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
OTUD5 promotes AML progression by stabilizing SLC7A11 to suppress ferroptosis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Tomivosertib

Commercial impact

medium

Successful dosing outcomes could enhance tomivosertib's market share and revenue potential, particularly if it demonstrates superior efficacy or safety compared to current AML treatments.

Regulatory impact

medium

The trial's design and outcomes will influence future regulatory submissions and labeling, especially if the dosing strategy proves effective in combination therapies.

What to watch

Key milestones include the completion of the dose finding phase and the determination of the recommended starting dose for combination therapies.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.